Gideon Nesher
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Gideon Nesher has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
M Sonnenblick
9 shared publicationsRonit Nesher
Department of Ophthalmology, Meir Medical Center, Kfar-Saba, Israel
5 shared publications- Gabriel Simon Breuer
Shaare Zedek Medical Center
3 shared publications M Mates
3 shared publicationsR Nesher
3 shared publicationsA Rubinow
2 shared publications
Latest Publications
- 1 August 2019
- Published by Elsevier in Autoimmunity Reviews
- Vol. 18 (8) , 831-834
Survival of patient with giant cell arteritis: Impact of vision loss and treatment with aspirin
- 1 August 2019
- Published by Elsevier in Autoimmunity Reviews
- Vol. 18 (8) , 831-834
Survival of patient with giant cell arteritis: Impact of vision loss and treatment with aspirin
- 23 March 2015
- Published by SAGE Publications in Lupus
- Vol. 24 (4-5) , 463-468
Severe ASIA syndrome associated with lymph node, thoracic, and pulmonary silicone infiltration following breast implant rupture: experience with four cases
Silicone has been considered biologically inert; thus it has been employed in many medical devices and nowadays is commonly used in plastic surgery for mammary prosthesis. It is well tolerated in most cases. However, autoimmune disorders and siliconomas with granulomatous reactions after silicone implant rupture have been described. We report cases of four women who developed systemic disorders following rupture of silicone breast implants resulting in lymph node and thoracic silicone infiltration. The symptoms in these cases, including arthralgia, myalgia, generalized weakness, severe fatigue, sleeping disturbances, cognitive impairment, memory loss, irritable bowel syndrome, and weight loss, clearly match the criteria of the recently defined autoimmune/inflammatory syndrome induced by adjuvants (ASIA).
- 23 March 2015
- Published by SAGE Publications in Lupus
- Vol. 24 (4-5) , 463-468
Severe ASIA syndrome associated with lymph node, thoracic, and pulmonary silicone infiltration following breast implant rupture: experience with four cases
Silicone has been considered biologically inert; thus it has been employed in many medical devices and nowadays is commonly used in plastic surgery for mammary prosthesis. It is well tolerated in most cases. However, autoimmune disorders and siliconomas with granulomatous reactions after silicone implant rupture have been described. We report cases of four women who developed systemic disorders following rupture of silicone breast implants resulting in lymph node and thoracic silicone infiltration. The symptoms in these cases, including arthralgia, myalgia, generalized weakness, severe fatigue, sleeping disturbances, cognitive impairment, memory loss, irritable bowel syndrome, and weight loss, clearly match the criteria of the recently defined autoimmune/inflammatory syndrome induced by adjuvants (ASIA).
- 28 March 2014
- Published by Springer Nature in Acta Neurologica Belgica
- Vol. 114 (4) , 269-272
Delayed diagnosis of subacute angle closure glaucoma in patients presenting with headaches
Subacute angle closure glaucoma (SACG) may lead to chronic angle closure glaucoma and irreversible vision loss. Headaches may be the sole presenting symptom. This study characterizes the medical course and symptoms of patients with SACG in whom headache was the major symptom. This retrospective observational study consisted of 30 consecutive patients, suffering from headaches and diagnosed with SACG, collected from the Glaucoma Service at the Ophthalmology Department of Meir Medical Center, Kfar Saba, Israel, a tertiary care referral facility. The primary study outcomes were reasons for referral, number of specialists visited and number of imaging studies performed before diagnosing SACG and headache characteristics. The majority of the patients experienced headaches once or twice a week. Four patients suffered a classic SACG pain involving the eye and frontal or hemicranial area. The mean time from onset of headaches to diagnosis was 2.6 years. The main reason for referral to the glaucoma clinic was consultation (53 %), and SACG was suspected by the referring physicians in two patients. Seventy-three percent of the patients were referred to at least three physicians in various medical specialties prior to referral to the glaucoma clinic. Patients usually do not volunteer history regarding headaches and clinicians often do not associate headaches with SACG in the absence of ocular symptoms. SACG should be included in the differential diagnosis in individuals older than 40 years presenting with late onset of headaches. Such patients should be referred to an ophthalmologist.
- 28 March 2014
- Published by Springer Nature in Acta Neurologica Belgica
- Vol. 114 (4) , 269-272
Delayed diagnosis of subacute angle closure glaucoma in patients presenting with headaches
Subacute angle closure glaucoma (SACG) may lead to chronic angle closure glaucoma and irreversible vision loss. Headaches may be the sole presenting symptom. This study characterizes the medical course and symptoms of patients with SACG in whom headache was the major symptom. This retrospective observational study consisted of 30 consecutive patients, suffering from headaches and diagnosed with SACG, collected from the Glaucoma Service at the Ophthalmology Department of Meir Medical Center, Kfar Saba, Israel, a tertiary care referral facility. The primary study outcomes were reasons for referral, number of specialists visited and number of imaging studies performed before diagnosing SACG and headache characteristics. The majority of the patients experienced headaches once or twice a week. Four patients suffered a classic SACG pain involving the eye and frontal or hemicranial area. The mean time from onset of headaches to diagnosis was 2.6 years. The main reason for referral to the glaucoma clinic was consultation (53 %), and SACG was suspected by the referring physicians in two patients. Seventy-three percent of the patients were referred to at least three physicians in various medical specialties prior to referral to the glaucoma clinic. Patients usually do not volunteer history regarding headaches and clinicians often do not associate headaches with SACG in the absence of ocular symptoms. SACG should be included in the differential diagnosis in individuals older than 40 years presenting with late onset of headaches. Such patients should be referred to an ophthalmologist.
- 1 February 2014
- Published by Elsevier in Journal of Autoimmunity
- Vol. 48-49, 73-75
The diagnosis and classification of giant cell arteritis
- 1 February 2014
- Published by Elsevier in Journal of Autoimmunity
- Vol. 48-49, 73-75
The diagnosis and classification of giant cell arteritis
- 1 February 2014
- Published by Elsevier in Journal of Autoimmunity
- Vol. 48-49, 76-78
Polymyalgia rheumatica – Diagnosis and classification
- 1 February 2014
- Published by Elsevier in Journal of Autoimmunity
- Vol. 48-49, 76-78
Polymyalgia rheumatica – Diagnosis and classification
- 1 October 2009
- Published by Elsevier in Seminars in Arthritis and Rheumatism
- Vol. 39 (2) , 96-107
Vasculitis of the Temporal Arteries in the Young
- 1 October 2009
- Published by Elsevier in Seminars in Arthritis and Rheumatism
- Vol. 39 (2) , 96-107
Vasculitis of the Temporal Arteries in the Young
- 24 October 2008
- Vol. 26, S30-4
Giant cell arteritis: intensity of the initial systemic inflammatory response and the course of the disease.
Giant cell arteritis (GCA) has a variable course. We assessed whether intensity of initial systemic inflammatory response (ISIR) can predict the course of GCA. Charts of 130 GCA patients were reviewed. ISIR intensity at presentation was determined by 5 parameters of inflammation: sedimentation rate >100 mm/h, thrombocytosis >400,000/microl, hemoglobin 11000/microl, and fever >37.5 degrees C. Patients were divided into 3 groups according to ISIR intensity: strong (4-5 parameters present, n=24), moderate (2-3 parameters, n=55) and weak ISIR (0-1 parameter, n=51). There were no significant differences between these groups regarding mean age, female:male ratio and the initial prednisone dose. At 1 year, 75% of patients in the strong ISIR group required >5 mg/d of prednisone, compared to 54% and 37% of patients with moderate or weak ISIR, respectively (p=0.015). Disease flares were more common in patients with strong ISIR during a 3-year period, compared to patients with moderate or weak ISIR (77%, 67% and 43%, respectively, p=0.013). Only 33% of patients with strong ISIR were able to discontinue steroids after 3 years, compared to 49% and 77% of patients with moderate and weak ISIR, respectively (p=0.003). GCA Patients with strong ISIR have prolonged disease course with more flares, requiring higher steroid doses. ISIR intensity should be taken into consideration when planning studies evaluating potential steroid-sparing agents, as response to treatment may vary in patients with different ISIR intensities.
- 24 October 2008
- Vol. 26, S30-4
Giant cell arteritis: intensity of the initial systemic inflammatory response and the course of the disease.
Giant cell arteritis (GCA) has a variable course. We assessed whether intensity of initial systemic inflammatory response (ISIR) can predict the course of GCA. Charts of 130 GCA patients were reviewed. ISIR intensity at presentation was determined by 5 parameters of inflammation: sedimentation rate >100 mm/h, thrombocytosis >400,000/microl, hemoglobin 11000/microl, and fever >37.5 degrees C. Patients were divided into 3 groups according to ISIR intensity: strong (4-5 parameters present, n=24), moderate (2-3 parameters, n=55) and weak ISIR (0-1 parameter, n=51). There were no significant differences between these groups regarding mean age, female:male ratio and the initial prednisone dose. At 1 year, 75% of patients in the strong ISIR group required >5 mg/d of prednisone, compared to 54% and 37% of patients with moderate or weak ISIR, respectively (p=0.015). Disease flares were more common in patients with strong ISIR during a 3-year period, compared to patients with moderate or weak ISIR (77%, 67% and 43%, respectively, p=0.013). Only 33% of patients with strong ISIR were able to discontinue steroids after 3 years, compared to 49% and 77% of patients with moderate and weak ISIR, respectively (p=0.003). GCA Patients with strong ISIR have prolonged disease course with more flares, requiring higher steroid doses. ISIR intensity should be taken into consideration when planning studies evaluating potential steroid-sparing agents, as response to treatment may vary in patients with different ISIR intensities.
- 1 August 2007
- Published by American Medical Association (AMA) in Archives of Ophthalmology (1950)
- Vol. 125 (8) , 1114
A Model for Quantifying Difficulty in Squeezing Eyedrops From Their Containers
Difficulty in squeezing eyedrops from bottles has been acknowledged as leading to reduced compliance. The purpose of this study was to develop objective means for assessing the force needed to extract eyedrops from bottles and to compare agents from the same pharmacological groups. A leverlike apparatus was designed for measurement of the required force. Comparing several topical agents, 3 bottles from the same batch were tested in a masked fashion and mean values were calculated. A total of 41 topical agents from 6 pharmacological groups were studied. The force required to squeeze an eyedrop ranged widely, from 700 to 2550g. Significant differences (P ≤ .05) were found within each pharmacological group. In conclusion, assessing the force needed to extract eyedrops is simple and repeatable. Significant differences were demonstrated among agents; however, the clinical relevance of these differences has yet to be proved.
- 1 August 2007
- Published by American Medical Association (AMA) in Archives of Ophthalmology (1950)
- Vol. 125 (8) , 1114
A Model for Quantifying Difficulty in Squeezing Eyedrops From Their Containers
Difficulty in squeezing eyedrops from bottles has been acknowledged as leading to reduced compliance. The purpose of this study was to develop objective means for assessing the force needed to extract eyedrops from bottles and to compare agents from the same pharmacological groups. A leverlike apparatus was designed for measurement of the required force. Comparing several topical agents, 3 bottles from the same batch were tested in a masked fashion and mean values were calculated. A total of 41 topical agents from 6 pharmacological groups were studied. The force required to squeeze an eyedrop ranged widely, from 700 to 2550g. Significant differences (P ≤ .05) were found within each pharmacological group. In conclusion, assessing the force needed to extract eyedrops is simple and repeatable. Significant differences were demonstrated among agents; however, the clinical relevance of these differences has yet to be proved.
- 13 April 2007
- Vol. 25, S15-7
The incidence of giant cell arteritis in Jerusalem over a 25-year period: annual and seasonal fluctuations.
Giant-cell arteritis (GCA) incidence is reported to be rising. A cyclic pattern of annual incidence rates and seasonal variations were reported by several groups. However, such fluctuations were not observed by others. We examined both annual and seasonal rates of GCA over a period of 25 years in Jerusalem. Charts of all patients diagnosed as GCA between 1980-2004 were reviewed. In 170 cases GCA was biopsy-proven. Thirty-six additional cases were included as they met the American College of Rheumatology GCA classification criteria. Data on the Jerusalem population throughout the study period was collected from the annual publications of the Israel Bureau of Statistics. Age- and sex-specific incidence rates per 100000 population aged>or=50 were calculated. For the whole period, the average age-adjusted incidence rate was 11.3 per 100000, and 9.5 for the biopsy-positive cases. The female: male ratio was 1.4:1. Cyclic fluctuations of GCA incidence with 3 distinctive peaks, 8-10 years apart, were observed. Altogether, there was no apparent increase in GCA incidence during this period. Seasonal variations were observed: in 192 patients we were able to estimate the time of onset of GCA symptoms. It showed a peak in the months of May and June, with the number of patients being twice as expected for this period (p<0.001). GCA onset was more common in late spring and early summer, and fluctuations in GCA annual incidence with 3 distinctive peaks were observed during a 25-year period. These suggest infectious or other environmental etiology, however thus far no such agents were proven.
- 13 April 2007
- Vol. 25, S15-7
The incidence of giant cell arteritis in Jerusalem over a 25-year period: annual and seasonal fluctuations.
Giant-cell arteritis (GCA) incidence is reported to be rising. A cyclic pattern of annual incidence rates and seasonal variations were reported by several groups. However, such fluctuations were not observed by others. We examined both annual and seasonal rates of GCA over a period of 25 years in Jerusalem. Charts of all patients diagnosed as GCA between 1980-2004 were reviewed. In 170 cases GCA was biopsy-proven. Thirty-six additional cases were included as they met the American College of Rheumatology GCA classification criteria. Data on the Jerusalem population throughout the study period was collected from the annual publications of the Israel Bureau of Statistics. Age- and sex-specific incidence rates per 100000 population aged>or=50 were calculated. For the whole period, the average age-adjusted incidence rate was 11.3 per 100000, and 9.5 for the biopsy-positive cases. The female: male ratio was 1.4:1. Cyclic fluctuations of GCA incidence with 3 distinctive peaks, 8-10 years apart, were observed. Altogether, there was no apparent increase in GCA incidence during this period. Seasonal variations were observed: in 192 patients we were able to estimate the time of onset of GCA symptoms. It showed a peak in the months of May and June, with the number of patients being twice as expected for this period (p<0.001). GCA onset was more common in late spring and early summer, and fluctuations in GCA annual incidence with 3 distinctive peaks were observed during a 25-year period. These suggest infectious or other environmental etiology, however thus far no such agents were proven.
- Open Access
- 5 April 2004
- Published by Wiley in Arthritis & Rheumatism
- Vol. 50 (4) , 1332-1337
Low‐dose aspirin and prevention of cranial ischemic complications in giant cell arteritis
Objective: Cranial ischemic complications such as cerebrovascular accidents (CVAs) and acute visual loss are among the leading causes of giant cell arteritis (GCA)–related morbidity. In this retrospective study, we evaluated the effect of treatment with low‐dose aspirin on the incidence of cranial ischemic complications in GCA.Methods: Charts of 175 consecutive patients in whom GCA was diagnosed between 1980 and 2000 were reviewed for medical data. Data for 166 patients who were followed up for at least 3 months were also available.Results: At the time of the diagnosis of GCA, 36 patients (21%) had already been receiving low‐dose aspirin (100 mg/day). In all cases, the indication for this treatment was ischemic heart disease. There were no significant differences between the aspirin‐treated and non–aspirin‐treated groups regarding the mean age of patients, the male‐to‐female ratio, duration of GCA‐related symptoms, rates of headaches, systemic symptoms, and jaw claudication, and the mean erythrocyte sedimentation rate, hemoglobin count, and platelet count. Cerebrovascular risk factors (hypertension, hyperlipidemia, or diabetes mellitus) were more common in the aspirin‐treated group (38.9% versus 20%;P= 0.03). Cranial ischemic complications were diagnosed in 43 patients at presentation: 30 patients had acute visual loss, 11 had CVAs, and 2 had both conditions simultaneously. Only 3 of the aspirin‐treated patients (8%) presented with cranial ischemic complications, compared with 40 (29%) of the non–aspirin‐treated patients (P= 0.01). Despite the use of steroid therapy, cranial ischemic complications developed in 14 of the 166 patients followed up for 3 months or longer. However, cranial ischemic complications developed in only 3% of the aspirin‐treated patients, compared with 13% of the patients treated with prednisone only (P= 0.02).Conclusion: These data suggest that low‐dose aspirin decreases the rate of visual loss and CVAs in patients with GCA.
- 5 April 2004
- Published by Wiley in Arthritis & Rheumatism
- Vol. 50 (4) , 1332-1337
Open AccessLow‐dose aspirin and prevention of cranial ischemic complications in giant cell arteritis
Objective: Cranial ischemic complications such as cerebrovascular accidents (CVAs) and acute visual loss are among the leading causes of giant cell arteritis (GCA)–related morbidity. In this retrospective study, we evaluated the effect of treatment with low‐dose aspirin on the incidence of cranial ischemic complications in GCA.Methods: Charts of 175 consecutive patients in whom GCA was diagnosed between 1980 and 2000 were reviewed for medical data. Data for 166 patients who were followed up for at least 3 months were also available.Results: At the time of the diagnosis of GCA, 36 patients (21%) had already been receiving low‐dose aspirin (100 mg/day). In all cases, the indication for this treatment was ischemic heart disease. There were no significant differences between the aspirin‐treated and non–aspirin‐treated groups regarding the mean age of patients, the male‐to‐female ratio, duration of GCA‐related symptoms, rates of headaches, systemic symptoms, and jaw claudication, and the mean erythrocyte sedimentation rate, hemoglobin count, and platelet count. Cerebrovascular risk factors (hypertension, hyperlipidemia, or diabetes mellitus) were more common in the aspirin‐treated group (38.9% versus 20%;P= 0.03). Cranial ischemic complications were diagnosed in 43 patients at presentation: 30 patients had acute visual loss, 11 had CVAs, and 2 had both conditions simultaneously. Only 3 of the aspirin‐treated patients (8%) presented with cranial ischemic complications, compared with 40 (29%) of the non–aspirin‐treated patients (P= 0.01). Despite the use of steroid therapy, cranial ischemic complications developed in 14 of the 166 patients followed up for 3 months or longer. However, cranial ischemic complications developed in only 3% of the aspirin‐treated patients, compared with 13% of the patients treated with prednisone only (P= 0.02).Conclusion: These data suggest that low‐dose aspirin decreases the rate of visual loss and CVAs in patients with GCA.